Table 4.
Cohort II prognostic value of markers
| Antigen | Prevalence N (%) |
Significance of hazard ratio adjusted for
|
|||
|---|---|---|---|---|---|
| Age, stage & borderline grade | Other markers, age, stage & borderline grade | ||||
| Signif.3 | Signif.4 | Signif3 | Signif4 | ||
| NASP | 145 (80%) | 0.20 | - - - | 0.26 | - - - |
| MRE11 | 126 (65%) | 0.99 | - - - | 0.99 | - - - |
| RCAS1 | 186 (95%) | 0.10 | - - - | 0.17 | - - - |
| RAD50 | 189 (97%) | 0.97 | - - - | 0.99 | - - - |
| Her2 | 23 (12%) | 0.07 | - - - | 0.26 | - - - |
| NBS1 | 96 (49%) | 0.75 | - - - | 0.88 | - - - |
| eIF5A | 175 (92%) | 0.04 | 0.32 | 0.06 | - - - |
| p53 | 97 (49%) | 0.28 | - - - | 0.62 | - - - |
3
Significance of the marker based on bootstrapped proportional hazards model.
4
Adjusted for multiple comparisons using Holm’s method.